JP2019523630A - Ｃｄ１３７に対する新規の二重特異性ポリペプチド - Google Patents

Ｃｄ１３７に対する新規の二重特異性ポリペプチド Download PDF

Info

Publication number
JP2019523630A
JP2019523630A JP2018555198A JP2018555198A JP2019523630A JP 2019523630 A JP2019523630 A JP 2019523630A JP 2018555198 A JP2018555198 A JP 2018555198A JP 2018555198 A JP2018555198 A JP 2018555198A JP 2019523630 A JP2019523630 A JP 2019523630A
Authority
JP
Japan
Prior art keywords
seq
antibody
light chain
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018555198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523630A5 (enExample
Inventor
エヴァ・ダレーン
ペーテル・エルマルク
クリスティーナ・フュアブリンク
ペル・ノルレン
アンナ・サール
ローラ・フォン・シャンツ
ニーナ・ヴェイトンマキ
サラ・フリッツェル
ジェシカ・ペーテルソン
ローラ・ヴァラス
Original Assignee
アリゲーター・バイオサイエンス・アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリゲーター・バイオサイエンス・アーベー filed Critical アリゲーター・バイオサイエンス・アーベー
Publication of JP2019523630A publication Critical patent/JP2019523630A/ja
Publication of JP2019523630A5 publication Critical patent/JP2019523630A5/ja
Priority to JP2021192091A priority Critical patent/JP2022058338A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
JP2018555198A 2016-04-22 2017-04-24 Ｃｄ１３７に対する新規の二重特異性ポリペプチド Pending JP2019523630A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021192091A JP2022058338A (ja) 2016-04-22 2021-11-26 Ｃｄ１３７に対する新規の二重特異性ポリペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201607046 2016-04-22
GB1607046.8 2016-04-22
PCT/EP2017/059656 WO2017182672A1 (en) 2016-04-22 2017-04-24 Novel bispecific polypeptides against cd137

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021192091A Division JP2022058338A (ja) 2016-04-22 2021-11-26 Ｃｄ１３７に対する新規の二重特異性ポリペプチド

Publications (2)

Publication Number Publication Date
JP2019523630A true JP2019523630A (ja) 2019-08-29
JP2019523630A5 JP2019523630A5 (enExample) 2020-05-21

Family

ID=58609424

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018555198A Pending JP2019523630A (ja) 2016-04-22 2017-04-24 Ｃｄ１３７に対する新規の二重特異性ポリペプチド
JP2021192091A Pending JP2022058338A (ja) 2016-04-22 2021-11-26 Ｃｄ１３７に対する新規の二重特異性ポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021192091A Pending JP2022058338A (ja) 2016-04-22 2021-11-26 Ｃｄ１３７に対する新規の二重特異性ポリペプチド

Country Status (14)

Country Link
US (2) US20190169308A1 (enExample)
EP (1) EP3445788B1 (enExample)
JP (2) JP2019523630A (enExample)
KR (1) KR102426765B1 (enExample)
CN (1) CN109195994A (enExample)
AU (1) AU2017252233A1 (enExample)
BR (1) BR112018071612A2 (enExample)
CA (1) CA3021618A1 (enExample)
DK (1) DK3445788T3 (enExample)
ES (1) ES2910365T3 (enExample)
IL (1) IL262482A (enExample)
MX (1) MX2018012897A (enExample)
RU (1) RU2018139339A (enExample)
WO (1) WO2017182672A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023516004A (ja) * 2020-02-28 2023-04-17 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｃｄ１３７コンストラクト、多重特異性抗体及びその使用
JP2023516941A (ja) * 2020-02-28 2023-04-21 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｃｄ１３７コンストラクト、多重特異性抗体及びその使用
WO2024085166A1 (ja) * 2022-10-19 2024-04-25 アステラス製薬株式会社 がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用
JP7791826B2 (ja) 2020-02-28 2025-12-24 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｃｄ１３７コンストラクト、多重特異性抗体及びその使用

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10532106B2 (en) 2014-10-29 2020-01-14 Bicyclerd Limited Bicyclic peptide ligands specific for MT1-MMP
CA3025345A1 (en) 2016-05-27 2017-11-30 Abbvie Biotherapeutics Inc. Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
US11214618B2 (en) 2016-06-20 2022-01-04 F-Star Therapeutics Limited LAG-3 binding members
US11214620B2 (en) 2016-06-20 2022-01-04 F-Star Therapeutics Limited Binding molecules binding PD-L1 and LAG-3
UA128304C2 (uk) 2016-07-14 2024-06-05 Ґенмаб А/С Мультиспецифічне антитіло до cd40 і cd137
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
CN117510643A (zh) * 2016-09-23 2024-02-06 美勒斯公司 调节细胞表达的生物活性的结合分子
MY200973A (en) 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc anticorpos anti-cd137 e métodos de uso dos mesmos
CA3070272A1 (en) 2017-07-20 2019-01-24 Aptevo Research And Development Llc Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
JP7290013B2 (ja) 2017-08-04 2023-06-13 ジェンマブ エー／エス Ｐｄ－ｌ１およびｃｄ１３７に結合する結合物質ならびにその使用
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
CN111683968B (zh) 2017-11-13 2024-07-05 克雷森多生物制剂有限公司 结合至cd137和psma的分子
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
CN111741976B (zh) 2017-12-19 2024-09-17 英沃克斯制药有限公司 包括pd-l1抗原结合位点的fc结合片段
CN109970865B (zh) * 2017-12-28 2022-10-04 上海细胞治疗研究院 一种cd137双向激活共刺激分子受体及其用途
JP2021514953A (ja) 2018-02-23 2021-06-17 バイスクルテクス・リミテッド 多量体二環式ペプチドリガンド
EP3765493A2 (en) 2018-03-12 2021-01-20 Genmab A/S Antibodies
KR20200139236A (ko) * 2018-04-04 2020-12-11 바이사이클티엑스 리미티드 헤테로탠덤 비사이클릭 펩티드 복합체
IL323061A (en) 2018-04-11 2025-10-01 Inhibrx Biosciences Inc Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
US12168691B2 (en) 2018-05-31 2024-12-17 Board Of Regents, The University Of Texas System VHS format bi-specific antibodies specific for HER2 and VEGF and use thereof
JP7557377B2 (ja) 2018-06-06 2024-09-27 レアダルティス、ソシエダッド リミターダ 三量体ポリペプチド複合体およびその使用
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
CA3106048A1 (en) 2018-07-12 2020-01-16 F-Star Beta Limited Antibody molecules that bind cd137 and ox40
GB201811450D0 (en) * 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811415D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
CN112423845B (zh) 2018-07-12 2024-07-30 F-星治疗有限公司 结合pd-l1和cd137的抗体分子
GB201811404D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
CN112789294A (zh) 2018-07-24 2021-05-11 印希比股份有限公司 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
CA3113539A1 (en) * 2018-10-10 2020-04-16 Zymeworks Inc. Antibody constructs binding 4-1bb and tumor-associated antigens and uses thereof
TW202506736A (zh) * 2018-10-11 2025-02-16 美商因荷布瑞克斯生物科學公司 5t4單域抗體及其治療性組合物
WO2020083277A1 (zh) * 2018-10-22 2020-04-30 上海一宸医药科技有限公司 一种双特异性抗体
BR112021010402A2 (pt) 2018-11-30 2021-08-24 Abl Bio Inc. Anticorpos biespecíficos anti-pd-l1/anti-4-1bb e uso dos mesmos
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
EP3898681A2 (en) * 2018-12-17 2021-10-27 Alligator Bioscience AB Polypeptides
GB201820556D0 (en) * 2018-12-17 2019-01-30 Alligator Bioscience Ab Novel polypeptides
US20220064325A1 (en) * 2018-12-17 2022-03-03 Alligator Bioscience Ab Novel polypeptides
EP3897725A4 (en) * 2018-12-21 2022-11-30 Actinium Pharmaceuticals, Inc. COMBINATION OF RADIOIMMUNOTHERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF CANCER
WO2020128526A1 (en) 2018-12-21 2020-06-25 Bicycletx Limited Bicyclic peptide ligands specific for pd-l1
TWI793395B (zh) * 2019-01-25 2023-02-21 大陸商信達生物製藥（蘇州）有限公司 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體
GB201905100D0 (en) * 2019-04-10 2019-05-22 Antibody Innovation Ltd Polypeptides and methods of use
CN113811541A (zh) 2019-05-09 2021-12-17 拜斯科技术开发有限公司 Ox40特异性的双环肽配体
CN114450306B (zh) * 2019-07-26 2024-04-05 Abl生物公司 抗egfr/抗4-1bb双特异性抗体及其用途
WO2021020846A1 (en) 2019-07-26 2021-02-04 Abl Bio Inc. Anti-her2/anti-4-1bb bispecific antibody and use thereof
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
CN112592404B (zh) * 2019-09-20 2023-07-25 上海交通大学医学院 抗体活性改造及其筛选方法
PL4464721T3 (pl) * 2019-10-03 2025-08-25 Bicycletx Limited Heterotandemowe kompleksy peptydów bicyklicznych
EP3816185A1 (en) 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
WO2021101346A1 (en) * 2019-11-21 2021-05-27 Dong-A St Co., Ltd. Anti-ror1/anti-4-1bb bispecific antibodies and uses thereof
US20230048361A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells and uses of same
WO2021137231A1 (en) 2019-12-31 2021-07-08 Kahr Medical Ltd. Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
JP2023509516A (ja) 2020-01-07 2023-03-08 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム がん治療のための改良型ヒトメチルチオアデノシン／アデノシン枯渇酵素変種
CA3146977A1 (en) * 2020-04-15 2021-10-21 Zymeworks Inc. Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
WO2021236658A1 (en) 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
US20230242658A1 (en) * 2020-06-30 2023-08-03 Nona Biosciences (Suzhou) Co., Ltd. 4-1bb-binding protein and use thereof
KR20230042524A (ko) 2020-08-07 2023-03-28 주식회사 유틸렉스 항-her2 / 항-4-1bb 이중특이적 항체 및 이의 용도
JP2023547507A (ja) * 2020-11-03 2023-11-10 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ 標的細胞限定的で共刺激性の二重特異性かつ２価の抗ｃｄ２８抗体
JP2024504388A (ja) * 2021-01-25 2024-01-31 ユーハン・コーポレイション 抗４－１ｂｂ／抗ｈｅｒ２二重特異性抗体の精製方法
CN118234750A (zh) * 2021-09-02 2024-06-21 纪念斯隆-凯特琳癌症中心 抗cd33抗体和其用途
US20240417482A1 (en) * 2021-10-12 2024-12-19 Concept To Medicine Biotech Co., Ltd. Single-domain 4-1bb antibodies
WO2023174521A1 (en) * 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
WO2024051752A1 (en) * 2022-09-06 2024-03-14 I-Mab Biopharma Co., Ltd. Multispecific constructs and uses thereof
WO2024061364A1 (zh) * 2022-09-22 2024-03-28 成都盛世君联生物技术有限公司 一种抗4-1bb纳米抗体及其制备和应用
WO2024117781A1 (ko) * 2022-11-29 2024-06-06 (주) 테라베스트 Cd137 세포외 도메인을 포함하는 융합단백질, 이를 발현하는 면역세포 및 이의 용도
WO2024143643A1 (ko) * 2022-12-30 2024-07-04 앱클론(주) Cd137에 특이적으로 결합하는 어피바디 및 이의 용도
WO2025035107A2 (en) * 2023-08-09 2025-02-13 Curadh Mtr, Inc. Trophoblast glycoprotein antibody compositions and methods of use
WO2025056180A1 (en) * 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015156268A1 (ja) * 2014-04-07 2015-10-15 中外製薬株式会社 免疫活性化抗原結合分子
WO2016004875A1 (en) * 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Combination therapy compositions and methods for treating cancers

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
ATE411342T1 (de) * 1999-11-18 2008-10-15 Oxford Biomedica Ltd Scfv antikörper gegen krankheiten-assoziierte moleküle
BR0108001A (pt) * 2000-02-01 2004-01-06 Tanox Inc Moléculas ativadoras de apc com ligação para cd-40
DK1272647T3 (en) 2000-04-11 2014-12-15 Genentech Inc Multivalent antibodies and uses thereof
TW200616662A (en) 2004-09-10 2006-06-01 Wyeth Corp Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PL2663580T3 (pl) * 2011-01-10 2017-08-31 Ct Atlantic Ltd. Terapia skojarzona obejmująca przeciwciała wiążące antygen związany z nowotworem
KR20160044598A (ko) 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
WO2013026839A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
WO2013041687A1 (en) * 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
US20150307620A1 (en) * 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
HRP20191824T1 (hr) * 2015-01-08 2020-01-24 BioNTech SE Agonistička sredstva za vezivanje tnf receptora
JP2018503399A (ja) * 2015-01-14 2018-02-08 コンパス セラピューティクス リミテッド ライアビリティ カンパニー 多特異性免疫調節抗原結合構築物
RU2017142008A (ru) * 2015-05-21 2019-06-24 Эллигейтор Биосайенс Аб Новые полипептиды
EP3585431A4 (en) * 2017-02-24 2020-12-16 MacroGenics, Inc. BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES
CA3070272A1 (en) 2017-07-20 2019-01-24 Aptevo Research And Development Llc Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015156268A1 (ja) * 2014-04-07 2015-10-15 中外製薬株式会社 免疫活性化抗原結合分子
WO2016004875A1 (en) * 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Combination therapy compositions and methods for treating cancers

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023516004A (ja) * 2020-02-28 2023-04-17 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｃｄ１３７コンストラクト、多重特異性抗体及びその使用
JP2023516941A (ja) * 2020-02-28 2023-04-21 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｃｄ１３７コンストラクト、多重特異性抗体及びその使用
JP7702961B2 (ja) 2020-02-28 2025-07-04 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｃｄ１３７コンストラクト、多重特異性抗体及びその使用
JP7702961B6 (ja) 2020-02-28 2025-07-17 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｃｄ１３７コンストラクト、多重特異性抗体及びその使用
JP7791826B2 (ja) 2020-02-28 2025-12-24 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｃｄ１３７コンストラクト、多重特異性抗体及びその使用
WO2024085166A1 (ja) * 2022-10-19 2024-04-25 アステラス製薬株式会社 がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用
JPWO2024085166A1 (enExample) * 2022-10-19 2024-04-25
JP7730432B2 (ja) 2022-10-19 2025-08-27 アステラス製薬株式会社 がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用

Also Published As

Publication number Publication date
BR112018071612A2 (pt) 2019-02-19
ES2910365T3 (es) 2022-05-12
JP2022058338A (ja) 2022-04-12
US20190169308A1 (en) 2019-06-06
US20220213213A1 (en) 2022-07-07
MX2018012897A (es) 2019-01-17
RU2018139339A (ru) 2020-05-22
WO2017182672A1 (en) 2017-10-26
RU2018139339A3 (enExample) 2020-09-28
CA3021618A1 (en) 2017-10-26
US12173082B2 (en) 2024-12-24
EP3445788B1 (en) 2022-01-19
KR102426765B1 (ko) 2022-07-29
EP3445788A1 (en) 2019-02-27
CN109195994A (zh) 2019-01-11
DK3445788T3 (en) 2022-04-11
KR20180135454A (ko) 2018-12-20
IL262482A (en) 2018-12-31
AU2017252233A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
US12173082B2 (en) Bispecific polypeptides against CD137
JP7419434B2 (ja) 新規のポリペプチド
US20230295325A1 (en) Novel anti-cd137 antibodies and uses thereof
US20190161555A1 (en) Bispecific Antibodies Directed Against OX40 and a Tumor-Associated Antigen
EP3699197A1 (en) Trispecific antibody combining specific tumor targeting and local immune checkpoint inhibition
US20220073635A1 (en) Novel polypeptides
US12448465B2 (en) Peptides
US20220064325A1 (en) Novel polypeptides
HK40004686B (en) Novel bispecific polypeptides against cd137
HK40003232A (en) Novel bispecific polypeptides against cd137
HK40073076A (en) Anti-cd137 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210806

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220207